

In this manuscript, rutin was evaluated for its antihypertensive effect using *In vitro* ACE inhibitory activity with captopril as standard. The *In vitro* ACE inhibition assay demonstrated that rutin exhibited antihypertensive activity by inhibiting angiotensin converting enzyme. By integrating *in silico* with *in vitro* studies of rutin, the authors concluded that rutin can act as novel therapeutic agent for the treatment of hypertension.

Many previous *in vitro* and *in vivo* reports had demonstrated that rutin exhibited antihypertensive activities. The authors should review previous antihypertensive activities of rutin in the introduction. Therefore the conclusion of this manuscript that rutin can act as novel therapeutic agent for the treatment of hypertension is not novel. The authors should emphasize the novelty of the methods used to evaluate the antihypertensive of the drug. Did the authors develop these methods?

In the manuscript, the authors used many abbreviations such as ADME, ADMET, GPCR, ACE, PASS, MCULE, SWISS ADME. Please give the name in full as it first appears in the manuscript. The general readers not in this field may not be able to understand.

In Table 7, please leave a space before and after \pm sign.

In the References section, the title of most of the references were given with only first word of the sentence in capital letter. However, Reference 3, 8, 12, and 14 have every words of the title in capital letters. Please be consistent.

Please check the grammar of the first sentence of the abstract. "Rutin was evaluated for its antihypertensive effect using *In vitro* ACE inhibitory activity using Captopril is used as standard." Please check the grammars of the whole manuscript

before re-submitting.